Johnson and Johnson gets CDSCO panel nod to study Paliperidone Palmitate
Advertisement
Pharmaceutical major, Johnson and Johnson has got a go ahead from the Subject Expert Committee SEC functional under Central Drug Standard Control Organization CDSCO to conduct Phase III clinical trial for antipsychotic Paliperidone Palmitate Prolonged Release Suspension for intramuscular injection 700 mg and 1000 mg, 6 months injection (PP6M) in India.
This came after the drug maker Johnson and Johnson represented comparative efficacy/safety data of PP6M Vs PP3M and PP6M vs PP1M of global clinical trial in global and ethnic Indian (or Indian Origin) patients.
For more details, check out the link given below:
JnJ Gets CDSCO Panel Nod To Study Antipsychotic Drug Paliperidone Palmitate
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.